sur VALBIOTIS (EPA:ALVAL)
Valbiotis Reports H1 2024 Financial Results and Strategic Developments
Valbiotis has published its interim financial statements for H1 2024, highlighting a robust cash position of €18.5M. The company marked a successful first commercial launch of Valbiotis@PRO Cholestérol in France, now available in over 200 pharmacies and wholesaler-distributors. The upcoming sales strategy includes launching TOTUM•63 in 2025.
New scientific accomplishments include promising results from the INSIGHT study on TOTUM•854, underscoring its potential in managing systolic blood pressure. The company plans to commercialize three other products in France, with a focus on targeted international expansion via licensing and distribution agreements.
Financially, Valbiotis reported a loss of €3.5M in net income, driven by increased marketing and sales efforts, despite a noteworthy gain in operating income from the termination of the Nestlé Health Science partnership. The company planned restructuring to streamline R&D activities, aiming for future savings of €2.2M annually. The strategic roadmap will be unveiled in Q1 2025.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VALBIOTIS